Iconic Therapeutics, Inc. Announces Phase 1 Wet AMD Study Results

ATLANTA--(BUSINESS WIRE)--Iconic Therapeutics, Inc. announced today that Dr. Christine Gonzales will present the results of its recently completed Phase 1 study of hI-con1TM in wet adult macular degeneration (wet AMD) patients at the American Academy of Ophthalmology Retina Subspecialty Day on Saturday, November 10, 2012 in Chicago. Dr. Gonzales, a Phase 1 investigator with the Retina and Vitreous Center of Southern Oregon, said “hI-con1TM has an entirely new and exciting mechanism of action for treatment of wet AMD. As an investigator in the phase 1 clinical trial, I was particularly impressed by the profound and early gains in vision and the significant reduction in OCT retinal thickness seen after a single intravitreal injection of the drug. In patients who received hI-con1TM with an anti-VEGF agent, the results were remarkable. I am very encouraged by the initial study results and look forward to the Phase 2 clinical trial.”